GLP-1 and SGLT-2 have the highest level of clinical evidence for use in this population, per the American Diabetes Association (ADA) guidelines.[3] Both GLP-1 and SGTL-2 products, such as Jardiance, have the ability to improve blood glucose control (hemoglobin A1c reduction), potentiate weight loss and provide a cardiovascular protective effect
Half of the participants self-injected low-dose semaglutide once a week
Guloyan V, Oganesian B, Baghdasaryan N, Yeh C, Singh M, Guilford F, Ting YS, Venketaraman V
These medicinesincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)work by mimicking the action of the naturally occurring GLP-1 hormone